Showing results (111-120 of 228) with videos related to
Sort By:
Pageof 23
Transplantation Direct|October 30, 2024
The Post-transplant Lymphoproliferative Disorders-Metagenomic Shotgun Microbial Sequencing (PTLD-MSMS) Study Methods and ProtocolVikas R Dharnidharka, Kristine M Wylie, Todd N Wylie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.Clinical Lymphoma, Myeloma & Leukemia|June 14, 2020
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort StudyFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.Blood|July 3, 2020
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomasMargery Gang, Nancy D Marin, Pamela Wong, et al.American Journal of Hematology|August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 studySusan O'Brien, Manish Patel, Brad S Kahl, et al.Blood|March 8, 2012
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz, Youn H Kim, Francine Foss, et al.Biorxiv : the Preprint Server for Biology|April 15, 2024
Onco-Circuit Addiction and Onco-Nutrient mTORC1 Signaling Vulnerability in a Model of Aggressive T Cell MalignancyXinxin Wang, Andrew E Cornish, Mytrang H Do, et al.Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.Blood Advances|July 26, 2023
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, et al.Pageof 23